| scholarly article | Q13442814 |
| P2093 | author name string | Masaru Sakurai | |
| Junji Kobayashi | |||
| Noboru Takekoshi | |||
| Hirokazu Kakuda | |||
| Masahiro Kakuda | |||
| P2860 | cites work | Hormone-Sensitive Lipase: Sequence, Expression, and Chromosomal Localization to 19 cent-q13.3 | Q24298488 |
| Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data | Q30871457 | ||
| Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 | ||
| Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 | ||
| Postprandial lipoprotein metabolism and atherosclerosis. | Q33785877 | ||
| Remnant lipoproteins as therapeutic targets | Q34086723 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. | Q35011476 | ||
| Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. | Q36268533 | ||
| Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study | Q37106470 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus | Q38077305 | ||
| Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus | Q38151450 | ||
| Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women | Q40192779 | ||
| Atherogenesis: a postprandial phenomenon | Q40237350 | ||
| Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
| Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin | Q44653784 | ||
| Renal glucosuria due to SGLT2 mutations | Q44863182 | ||
| Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes | Q46404958 | ||
| Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice | Q46579468 | ||
| Postprandial triglyceride response in visceral obesity in men. | Q48033188 | ||
| Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. | Q51022740 | ||
| Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
| The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes. | Q51317481 | ||
| Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. | Q51562831 | ||
| Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. | Q51943609 | ||
| Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women | Q61162458 | ||
| Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation | Q77409872 | ||
| Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice | Q83629703 | ||
| Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label | Q87261695 | ||
| P433 | issue | 5 | |
| P921 | main subject | glucose | Q37525 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 403-409 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Journal of Clinical Medicine Research | Q26842453 |
| P1476 | title | The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study | |
| P478 | volume | 9 |
| Q33763316 | Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data |
| Q64110036 | Long-term safety and efficacy of the sodium glucose cotransporter 2 inhibitor tofogliflozin added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus (J-STEP/GLP): a 52-week open-label, multicenter, post-mar |
| Q60920900 | Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes |
| Q55513324 | Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy. |
Search more.